To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Dynamics of three-dimensi… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are under going androgen deprivation and radiation therapies

Journal article
Authors L. Wark
T. Klonisch
Julius Adebayo Awe
C. LeClerc
B. Dyck
H. Quon
S. Mai
Published in Urologic Oncology-Seminars and Original Investigations
Volume 35
Issue 3
ISSN 1078-1439
Publication year 2017
Published at Institute of Biomedicine, Department of Medical and Clinical Genetics
Language en
Links 10.1016/j.urolonc.2016.10.018
Keywords High-risk prostate cancer, Telomeres, Circulating tumor cells, Biomarkers, organization
Subject categories Urology and Nephrology, Cancer and Oncology

Abstract

Introduction:Accurate assessment and monitoring of the therapeutic efficacy of locally advanced prostate cancer remains a major clinical challenge. Contrary to prostate biopsies, circulating tumor cells (CTCs) are a cellular source repeatedly obtainable by blood sampling and could serve as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate and enumerate CTCs from the blood of 20 patients with high-risk (any one of cT3, Gleason 810, or prostate-specific antigen>20 ng/ml), nonmetastatic, and treatment-naive prostate cancer before and after androgen deprivation therapy (ADT) and radiation therapy (RT). Materials and methods:We performed 3D telomere-specific quantitative fluorescence in situ hybridization on isolated CTCs to determine 3D telomere profiles for each patient before and throughout the course of both ADT and RT. Results:Based on the distinct 3D telomere signatures of CTC before treatment, patients were divided into 3 groups. ADT and RT resulted in distinct changes in 3D telomere signatures of CTCs, which were unique for each of the 3 patient groups. Conclusion:The ability of 3D telomere analysis of CTCs to identify disease heterogeneity among a clinically homogeneous group of patients, which reveals differences in therapeutic responses, provides a new opportunity for better treatment monitoring and management of patients with high-risk prostate cancer. (C) 2017 The Authors. Published by Elsevier Inc.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?